Last reviewed: June 15, 2026
Last updated: June 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Questions about the future of compounded semaglutide arise regularly as regulatory agencies review GLP-1 medications and their manufacturing standards. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver semaglutide and other peptide therapies legally across all 50 states, with no insurance requirement. Understanding the difference between compounded and brand medications helps patients make informed decisions about their weight loss treatment.
What Is Happening With Compounded Semaglutide Supply
Compounded semaglutide has become more widely available since brand-name Ozempic and Wegovy faced supply constraints in 2022 and 2023. Licensed 503A compounding pharmacies legally manufacture semaglutide under state pharmacy boards and federal oversight, following USP <797> standards for sterile preparation. PlexusDx sources all medications from these regulated facilities, ensuring quality and safety standards equivalent to traditional pharmaceutical manufacturing.
The FDA has not banned compounded semaglutide. Instead, regulatory focus has centered on unlicensed sellers, counterfeit products, and 503B outsourcing facilities that operate outside traditional pharmacy oversight. This distinction matters: 503A compounders work within state licensing frameworks and direct pharmacist-patient relationships, while 503B facilities serve as wholesalers and are held to different standards. PlexusDx commitment to 503A-only sourcing reflects best practices for patient safety and regulatory compliance.
Key Regulatory Changes Affecting GLP-1 Medications
In 2023 and 2024, the FDA issued warning letters to some compounding operations for quality control failures and misleading marketing claims. These actions targeted specific facilities with documented deficiencies—not the entire compounded medication sector. The agency has simultaneously maintained that 503A compounding serves a legitimate role when brand medications are unavailable or unaffordable for patients. PlexusDx navigates this landscape by maintaining transparent sourcing, third-party testing protocols, and direct engagement with patient communities.
State pharmacy boards continue to regulate compounded medications through licensing, inspection, and quality assurance programs. Many state boards have strengthened oversight of GLP-1 compounders specifically, requiring additional credentials and sterility testing. PlexusDx operates within these state-level requirements and proactively pursues certifications that exceed minimum standards, including USP verification and pharmaceutical-grade ingredient sourcing.
Why Patients Choose Compounded Semaglutide Over Brand Options
Compounded semaglutide injection costs significantly less than brand-name Ozempic or Wegovy. PlexusDx offers compounded semaglutide starting at $149 per month—a flat rate that holds regardless of dose escalation, meaning patients never face surprise price increases as their treatment advances. Brand medications often cost $900–$1,300 monthly without insurance, placing effective weight loss therapy out of reach for millions of Americans. Compounded alternatives expand access to evidence-based GLP-1 therapy for self-pay patients, those with high-deductible plans, and individuals using HSA or FSA funds.
Availability represents another critical advantage. Brand supply chains have experienced recurring shortages, particularly during high-demand seasons. Licensed 503A compounding pharmacies operate with greater supply flexibility because they manufacture on-demand using pharmaceutical-grade raw materials. PlexusDx patients benefit from consistent access without the months-long wait times that sometimes accompany branded products. Additionally, some patients qualify for oral semaglutide or tirzepatide formulations through PlexusDx, options that provide flexibility for those preferring injection-free protocols.
PlexusDx Commitment to Safety and Transparency in GLP-1 Therapy
PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies that maintain state licensing, USP compliance, and transparent quality documentation. Each patient's medication comes with full ingredient lists, batch testing results, and clear sourcing information—no hidden supply chains or unlicensed manufacturers. The company's medical team reviews every patient's metabolic history and genetic factors before recommending a specific GLP-1 compound, ensuring personalized dosing strategies and risk assessment.
PlexusDx also offers the Precision Peptide Genetic Test, a peptide-pathway analysis that identifies how a patient's body responds to GLP-1 compounds like semaglutide and tirzepatide. This test maps 14 metabolic pathways and 49 peptide interactions, helping clinicians predict which medication and formulation delivers optimal results for each individual. By combining licensed compounding, transparent sourcing, and genetic personalization, PlexusDx positions compounded GLP-1 therapy as a medically sound option that rivals traditional pharmaceutical models in safety and efficacy.
What the Future Likely Holds for Compounded GLP-1 Access
Industry experts anticipate continued FDA oversight focused on quality standards rather than outright bans on compounded GLP-1 medications. As brand supply chains stabilize and competition increases, prices for both branded and compounded options may eventually converge. However, compounding will likely remain a critical access point for patients seeking affordable, personalized treatment. PlexusDx monitors regulatory developments closely and adjusts sourcing and formulations to meet evolving standards, ensuring uninterrupted patient access.
The peptide weight loss market will continue expanding beyond semaglutide alone. PlexusDx already offers compounded tirzepatide, oral formulations, and dual-compound products like GLP-Squared that combine semaglutide and tirzepatide in single injections. These innovations reflect the evolving landscape of GLP-1 therapy and ensure patients have multiple evidence-based options regardless of regulatory shifts. PlexusDx commitment remains constant: safe, affordable, and medically personalized weight loss therapy delivered through licensed, transparent channels across all 50 states.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is compounded semaglutide still legal to buy and use in 2024?
Yes. Compounded semaglutide manufactured by licensed 503A compounding pharmacies remains legal and FDA-recognized as a legitimate medication option when brand supplies are limited or unaffordable. PlexusDx operates within federal and state regulatory frameworks, sourcing exclusively from licensed pharmacies with documented quality standards and state licensing oversight.
How does compounded semaglutide differ from brand-name Ozempic or Wegovy?
Compounded semaglutide uses the identical active pharmaceutical ingredient as brand medications but is manufactured by licensed compounding pharmacies rather than Novo Nordisk. The clinical mechanism—activation of GLP-1 receptors to reduce appetite and improve blood sugar—is identical. Key differences include cost (compounded starts at $149/mo), availability, and customization options. PlexusDx compounded semaglutide undergoes third-party testing to verify potency and purity.
Why is PlexusDx compounded semaglutide so much cheaper than brand options?
Compounded semaglutide avoids the research, regulatory approval, and marketing expenses that pharmaceutical companies invest in branded drugs. Licensed 503A compounding pharmacies operate with lower overhead and manufacture on-demand, reducing inventory costs. PlexusDx passes these savings to patients, offering compounded semaglutide injection at $149/mo flat rate—no flat per-compound pricing increases—plus HSA/FSA eligibility for additional savings.
What quality assurance does PlexusDx use to ensure safe compounded medications?
PlexusDx partners exclusively with 503A compounding pharmacies maintaining USP <797> sterile compounding standards, state pharmacy licensing, and third-party batch testing. Every medication includes full documentation of ingredients, manufacturing dates, and potency verification. Patients receive transparent sourcing information and can request batch testing results. This level of oversight exceeds many compounding operations and matches pharmaceutical manufacturing standards.
How does the Precision Peptide Genetic Test help optimize my semaglutide therapy?
The PlexusDx Precision Peptide Genetic Test identifies your genetic variations in GLP-1 receptor function (GLP1R rs6923761), appetite regulation (FTO rs9939609), and related pathways that influence how your body responds to semaglutide and other peptides. This $99 test maps 14 metabolic pathways and 150+ genetic insights, allowing your clinician to predict optimal dosing, formulation choice (injection vs. oral), and potential side effect risk—enabling truly personalized GLP-1 therapy rather than one-size-fits-all dosing.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What to Expect After First Dose of Tirzepatide: Your Guide to Starting a Personalized Weight Loss Journey
TrimRx vs Calibrate: Comparing GLP-1 Telehealth Providers